Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Delhaize, Dexia, Omega Pharma, Vastned: Benelux Equity Preview

The following companies may have unusual price changes in Benelux markets. Stock symbols are in parentheses, and prices are from the previous close.

The AEX-Index in Amsterdam declined 3.2 percent to 300.85. Belgium’s Bel20 Index sank 2.9 percent to 2,223.67. Luxembourg’s LuxX Index tumbled 3.6 percent to 1,232.67.

Dutch stocks:

Vastned Offices/Industrial NV (VNOI NA): The property fund that plans to merge with Nieuwe Steen Investments NV said its first-half direct investment result fell to 10.1 million euros ($14.3 million) from 13.1 million euros a year earlier. The shares lost 3.4 percent to 9.50 euros.

Vastned Retail NV (VASTN NA): The Dutch owner of shopping centers in the Netherlands, Spain, France and Belgium said its first-half direct investment result was unchanged at 33.6 million euros. The shares fell 4.3 percent to 42.90 euros.

Belgian stocks:

Delhaize Group SA (DELB BB): The owner of the Food Lion supermarkets in the U.S. may say second-quarter net income rose to 118.8 million euros, according to the average of six analyst estimates compiled by Bloomberg, from 114 million euros a year earlier. Delhaize retreated 0.3 percent to 47.03 euros.

Dexia SA (DEXB BB): Belgium’s largest bank by assets reported a record quarterly net loss of 4.03 billion euros, which included a 377 million-euro pretax writedown of Greek debt holdings, and said central-bank funding increased to about 34 billion euros at the end of June. Dexia decreased 1.5 percent to 1.66 euros.

Omega Pharma NV (OME BB): Belgium’s biggest supplier of pharmacy products reported first-half earnings excluding some items rose to 1.45 euros a share from 1.44 euros a year earlier. Earnings missed the 1.52 euro-a-share median estimate of five analysts surveyed by Bloomberg News. Omega Pharma dropped 2.6 percent to 30.77 euros.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.